Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CODEXIS, INC. Director's Dealing 2010

Apr 29, 2010

33607_dirs_2010-04-29_2adc5426-2ce6-4cd2-b311-f964d3a4fbf8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CODEXIS INC (CDXS)
CIK: 0001200375
Period of Report: 2010-04-27

Reporting Person: SULAT JAMES R (Director, 10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2010-04-27 Common Stock C 4040404 Acquired 4707070 Indirect
2010-04-27 Common Stock C 1080146 Acquired 5787216 Indirect
2010-04-27 Common Stock C 169892 Acquired 5957108 Indirect

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2010-04-27 Series A Preferred Stock $ C 4040404 Disposed Common Stock (4040404) Direct
2010-04-27 Series B Preferred Stock $ C 1080146 Disposed Common Stock (1080146) Direct
2010-04-27 Series D Preferred Stock $ C 169892 Disposed Common Stock (169892) Direct
2010-04-27 Warrant to Purchase Series D Preferred Stock $5.96 J 30816 Disposed 2013-05-25 Series D Preferred Stock (30816) Direct
2010-04-27 Warrant to Purchase Common Stock $5.96 J 30816 Acquired 2013-05-25 Common Stock (30816) Direct

Footnotes

F1: Reflects a 2-for-3 reverse stock split of the Issuer's outstanding securities effected immediately prior to the effectiveness of the Issuer's S-1 Registration Statement (Commission File No. 333-164044).

F2: Each share of Series A Preferred Stock automatically converted into Common Stock on a 1.010101-for-1 basis upon the closing of the Issuer's initial public offering.

F3: Held by Maxygen, Inc. ("Maxygen"). James R. Sulat, a member of the Issuer's board of directors, is the Chief Executive Officer, Chief Financial Officer and a member of the board of directors of Maxygen, and, as such, may be deemed to be the beneficial owner of the securities held by Maxygen. Mr. Sulat disclaims beneficial ownership of all securities held by Maxygen, except to the extent of his pecuniary interest therein.

F4: Each share of Series B Preferred Stock automatically converted into Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.

F5: Each share of Series D Preferred Stock automatically converted into Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.

F6: The expiration date is not relevant to the conversion of these securities.

F7: Upon completion of the Issuer's initial public offering, the warrant to purchase shares of Series D Preferred Stock automatically converted into a warrant to purchase an equal number of shares of the Issuer's Common Stock. Disposition of Warrant to Series D Preferred Stock and acquisition of Warrant to Purchase Common Stock listed solely for the purpose of reporting such conversion of the shares underlying the security.

F8: This warrant is immediately exercisable.